Prognostic Impact of MYCN Amplification, 1p Deletion and 11q Deletion in Neuroblastoma Patients


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Neuroblastoma is characterized by wide clinical heterogeneity from tumors prone to spontaneous regression to highly aggressive disease that requires multimodal chemotherapy with autologous stem cells transplantation. Patient’s age and stage of the disease were described as prognostic factors. Different genetic aberrations were analyzed as potential predictive signs of poor outcome. MYCN gene amplification, 1p and 11q deletions are associated with aggressive tumor behavior, advanced stage of the disease and unfavorable outcome. In current report we analyzed molecular mechanisms and prognostic significance of indicated genetics abnormalities.

全文:

受限制的访问

作者简介

Aleksandr Druy

Institute of Medical Cell Technologies

Email: dr-drui@yandex.ru
Researcher

Grigoriy Tsaur

Institute of Medical Cell Technologies

Email: tsaur@mail.ru
MD, PhD. Head of Molecular Biology Laboratory

Yegor Shorikov

Institute of Medical Cell Technologies

Email: cohc@bk.ru
MD, PhD. Head of Pediatric Oncology Department

Aleksandr Popov

Institute of Medical Cell Technologies

Email: uralmolgen@gmail.ru
MD, PhD

Leonid Savelyev

Institute of Medical Cell Technologies

Email: sav7000@yandex.ru
MD, PhD. Head of Laboratory Department

Sergey Tsvirenko

Institute of Medical Cell Technologies

Email: sv50@rambler.ru
MD, PhD, Professor. Head of Clinical Laboratory Diagnostics Department

Larisa Fechina

Institute of Medical Cell Technologies

Email: cohc@bk.ru
MD, PhD. Head of Pediatric Oncology and Hematology Center

参考

  1. Друй А. Е., Цаур Г. А., Семенихина Е. Р. и др. Амплификации гена MYCN при нейробластоме. Методы выявления и прогностическое значение // Мед. генетика. — 2012. — № 9. — С. 25–30.
  2. Фейгин B. Л. Основы мета-анализа: теория и практика // Международный журнал медицинской практики. — 1999. — № 7. — С. 7–13.
  3. Ambros P. F., Ambros I. M., Brodeur G. M. et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee // Br. J. Cancer. — 2009. — N 5, 100(9). — P. 1471–1482.
  4. Ando K., Ohira M., Ozaki T. et al. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation // Int. J. Cancer. — 2008. — N 1;123(9). — P. 2087–2094.
  5. Attiyeh E. F., London W. B., Mossé Y. P. et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma // N. Engl. J. Med. — 2005. — N. 24, 353(21). — P. 2243–2253.
  6. Bagchi A., Papazoglu C., Wu Y. et al. CHD5 is a tumor suppressor at human 1p36 // Cell. — 2007. — N. 9, 128(3). — P. 459–475.
  7. Bown N., Lastowska M., Cotterill S. et al. 17q gain in neuroblastoma predicts adverse clinical outcome. U. K. Cancer Cytogenetics Group and the U. K. Children's Cancer Study Group // Med. Pediatr. Oncol. — 2001. — N. 36(1). — P. 14–19.
  8. Brodeur G. M., Green A. A., Hayes F. A. et al. Cytogenetic features of human neuroblastomas and cell lines // Cancer Res. — 1981. — N. 41(11). — P. 4678–4686.
  9. Brodeur G. M., Seeger R. C., Schwab M. et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage // Science. — 1984. — N. 8, 224(4653). — P. 1121–1124.
  10. Caron H., van Sluis P., de Kraker J. et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma // N. Engl. J. Med. — 1996. — N. 25;334(4). — P. 225–230.
  11. Chatten J., Shimada H., Sather H. N. et al. Prognostic value of histopathology in advanced neuroblastoma: a report from the Childrens Cancer Study Group // Hum Pathol. — 1988. — N. 19(10). — P. 1187–1198.
  12. Christiansen H., Lampert F. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma // Br. J. Cancer. — 1988. — N. 57 (1). — P. 121–126.
  13. Cohn S. L., Pearson A. D., London W. B. et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report // J. Clin. Oncol. — 2009. — N. 10, 27(2). — P. 289–297.
  14. D'Angio G. J., Evans A. E., Koop C. E. Special pattern of widespread neuroblastoma with a favourable prognosis // Lancet. — 1971. — N. 22, 1(7708). — P. 1046–1049.
  15. Evans A. E., Gerson J., Schnaufer L. Spontaneous regression of neuroblastoma // Natl. Cancer Inst. Monogr. — 1976. — N. 44. — P. 49–54.
  16. Fong C. T., Dracopoli N. C., White P. S. et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification // Proc. Natl. Acad. Sci. USA. — 1989. — N. 86(10). — P. 3753–3757.
  17. Gilbert F., Feder M., Balaban G. et al. Human neuroblastomas and abnormalities of chromosomes 1 and 17 // Cancer Res. — 1984. — N. 44(11). — P. 5444–5449.
  18. Giordani L., Iolascon A., Servedio V. et al. Two regions of deletion in 9p22-p24 in neuroblastoma are frequently observed in favorable tumors // Cancer Genet. Cytogenet. — 2002. — N. 135(1). — P. 42–47.
  19. Grady E. F., Schwab M., Rosenau W. Expression of N-myc and c-src during the development of fetal human brain // Cancer Res. — 1987. — N. 1, 47(11). — P. 2931–2936.
  20. Guo C., White P. S., Weiss M. J. et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas // Oncogene. — 1999. — N. 2, 18(35). — P. 4948–4957.
  21. Ladenstein R., Ambros I. M., Pötschger U. et al. Prognostic significance of DNA di-tetraploidy in neuroblastoma // Med. Pediatr. Oncol. — 2001. — N. 36(1). — P. 83–92.
  22. Lastowska M., Cotterill S., Pearson A. D. et al. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U. K. Children's Cancer Study Group and the U. K. Cancer Cytogenetics Group // Eur. J. Cancer. — 1997. — N. 33(10). — P. 1627–1633.
  23. Look A. T., Hayes F. A., Shuster J. J. et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study // J Clin Oncol. — 1991. — N. 9(4). — P. 581–591.
  24. Manohar C. F., Salwen H. R., Brodeur G. M., Cohn S. L. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma // Genes Chromosomes Cancer. — 1995. — N. 14(3). — P. 196–203.
  25. Maris J. M., White P. S., Beltinger C. P. et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma // Cancer Res. — 1995. — N. 15, 55(20). — P. 4664–4669.
  26. Matthay K. K., Villablanca J. G., Seeger R. C. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group // N. Engl. J. Med. — 1999. — N. 14, 341 (16). — P. 1165–1173.
  27. Ohtsu K., Hiyama E., Ichikawa T. et al. Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1 // Clin. Cancer Res. — 1997. — N. 3(7). — P. 1221–1228.
  28. Perez C. A., Matthay K. K., Atkinson J. B. et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study // J. Clin. Oncol. — 2000. — N. 18(1). — P. 18–26.
  29. Pession A., De Bernardi B., Perri P. et al. The prognostic effect of amplification of the MYCN oncogene in neuroblastoma. The preliminary results of the Italian Cooperative Group for Neuroblastoma (GCINB) // Pediatr Med. Chir. — 1994. — N. 16(3). — P. 211–218.
  30. Raschellà G., Cesi V., Amendola R. et al. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification // Cancer Res. — 1999. — N. 15, 59(14). — P. 3365–3368.
  31. Santo E. E., Ebus M. E., Koster J. et al. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma // Oncogene. — 2012. — N. 22, 31(12). — P. 1571–1581.
  32. Seeger R. C., Brodeur G. M., Sather H. et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas // N. Engl. J. Med. — 1985. — N. 31, 313(18). — P. 1111–1116.
  33. Shimada H., Ambros I. M., Dehner L. P. et al. The International Neuroblastoma Pathology Classification (the Shimada system) // Cancer. — 1999. — N. 15, 86(2). — P. 364–372.
  34. Simon T., Spitz R., Faldum A. et al. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status // J. Pediatr Hematol. Oncol. — 2004. — N. 26(12). — P. 791–796.
  35. Thompson P. M., Gotoh T., Kok M. et al. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system // Oncogene. — 2003. — N. 20, 22(7). — P. 1002–1011.
  36. Tonini G. P., Boni L., Pession A. et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children // J. Clin. Oncol. — 1997. — N. 15(1). — P. 85–93.
  37. Vandesompele J., Van Roy N., Van Gele M. et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization // Genes Chromosomes Cancer. — 1998. — N. 23(2). — P. 141–152.
  38. Weber A., Imisch P., Bergmann E., Christiansen H. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma // J. Clin. Oncol. — 2004. — N. 1 22(13). — P. 2681–2690.
  39. Wei J. S., Song Y. K., Durinck S. et al. The MYCN oncogene is a direct target of miR-34a // Oncogene. — 2008. — N. 4, 27(39). — P. 5204–5213.
  40. Westermann F, Schwab M. Genetic parameters of neuroblastomas // Cancer Lett. — 2002. — N. 28, 184(2). — P. 127–147.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Druy A.Y., Tsaur G.A., Shorikov Y.V., Popov A.M., Savelyev L.I., Tsvirenko S.V., Fechina L.G., 2013

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 69634 от 15.03.2021 г.


##common.cookie##